Gebasaxturev
- Generic Name
- Gebasaxturev
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2122169-83-7
- Unique Ingredient Identifier
- 4B57CWT710
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013)
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 76
- Registration Number
- NCT04521621
- Locations
- 🇫🇷
Hopital La Timone ( Site 0051), Marseille, Bouches-du-Rhone, France
🇨🇦Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0032), Montreal, Quebec, Canada
🇩🇪Universitaetsklinikum Tuebingen ( Site 0171), Tuebingen, Baden-Wurttemberg, Germany
Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2020-03-10
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 90
- Registration Number
- NCT04303169
- Locations
- 🇮🇹
Istituto Europeo di Oncologia ( Site 3301), Milano, Italy
🇮🇹Policlinico Le Scotte - A.O. Senese ( Site 3377), Siena, Italy
🇺🇸The Angeles Clinic and Research Institute ( Site 3009), Los Angeles, California, United States
A Safety Study of Two Intratumoural Doses of Coxsackievirus Type A21 in Melanoma Patients (PSX-X03)
- First Posted Date
- 2007-02-21
- Last Posted Date
- 2019-07-01
- Lead Sponsor
- Viralytics
- Target Recruit Count
- 9
- Registration Number
- NCT00438009
- Locations
- 🇦🇺
Princess Alexandra Hospital, Brisbane, Queensland, Australia
Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma (PXS-X02)
Phase 1
Completed
- Conditions
- First Posted Date
- 2005-10-10
- Last Posted Date
- 2019-06-27
- Lead Sponsor
- Viralytics
- Target Recruit Count
- 3
- Registration Number
- NCT00235482
- Locations
- 🇦🇺
Melanoma Unit, Mater Misericordiae Hospital, Newcastle, New South Wales, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath